BioNTech Q1 results, corporate update

 

• More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021

• Signed agreements for over 1.8 billion doses of BNT162b2 in 2021 and first contracts signed for periods 2022 and beyond

• Announced planned expansion of global footprint to Asia with establishment of first regional headquarters for south east Asia in Singapore, including a fully-integrated and state-of-the art mRNA manufacturing facility

• In oncology, a first-in-human Phase 1 trial started for the neoantigen-targeting T cell therapy, BNT221. The development of BioNTech’s oncology pipeline has continued to accelerate with 14 product candidates now in 15 ongoing trials

Conference call and webcast scheduled for May 10, 2021, at 8:00 a.m. ET (2:00 p.m. CET)

Update on current signed COVID-19 vaccine order book:

Estimated COVID-19 vaccine revenues to BioNTech upon delivery of currently signed supply contracts of ~1.8 billion doses is ~€12.4 billion. This revenue estimate reflects: Additional revenues related to further supply contracts for deliveries in 2021 expected with first contracts in place for 2022 and beyond. Full year 2021 manufacturing capacity now targeting 3 billion doses and more than 3 billion doses for the year 2022.

On Track with Previously Stated 2021 Financial Outlook

https://finance.yahoo.com/news/biontech-announces-first-quarter-2021-110000704.html